A. C. NATHWANI ET AL: "Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates", BLOOD, vol. 109, no. 4, 15 February 2007 (2007-02-15), US, pages 1414 - 1421, XP055426703, ISSN: 0006-4971, DOI: 10.1182/blood-2006-03-010181 (B1)

BIOMARIN: "A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector- Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A (NCT02576795)", 14 June 2017 (2017-06-14), US, XP055428656, ISBN: 978-1-118-00490-6, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT02576795> [retrieved on 20171124] (B1)

DWAIPAYAN SEN ET AL: "Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy", SCIENTIFIC REPORTS, vol. 6, 13 May 2013 (2013-05-13), XP055076741, DOI: 10.1038/srep01832 (B1)

ELIE DOLGIN: "Early clinical data raise the bar for hemophilia gene therapies", NATURE BIOTECHNOLOGY, vol. 34, no. 10, 1 October 2016 (2016-10-01), pages 999 - 1001, XP055428494 (B1)

UNIQURE BIOPHARMA: "Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B (NCT02396342)", 3 February 2017 (2017-02-03), XP055428670, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02396342> [retrieved on 20171124] (B1)

FRANK W.G. LEEBEEK ET AL: "Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B", BLOOD, vol. 128, 2 December 2016 (2016-12-02), pages 2314, XP055428470 (B1)

HILDINGER MARKUS ET AL: "Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 13, 1 July 2001 (2001-07-01), pages 6199 - 6203, XP002306404, ISSN: 0022-538X, DOI: 10.1128/JVI.75.13.6199-6203.2001 (B1)

LONG BRIAN R. ET AL: "The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 13, 14 June 2019 (2019-06-14), GB, pages 440 - 452, XP093117308, ISSN: 2329-0501, Retrieved from the Internet <URL:https://dx.doi.org/10.1016/j.omtm.2019.03.006> DOI: 10.1016/j.omtm.2019.03.006 (B1)

SYLVIE BOUTIN ET AL: "Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors", HUMAN GENE THERAPY, vol. 21, no. 6, 1 June 2010 (2010-06-01), pages 704 - 712, XP055172076, ISSN: 1043-0342, DOI: 10.1089/hum.2009.182 (B1)

F. MINGOZZI ET AL: "Immune responses to AAV vectors: overcoming barriers to successful gene therapy", BLOOD, vol. 122, no. 1, 17 April 2013 (2013-04-17), pages 23 - 36, XP055175008, ISSN: 0006-4971, DOI: 10.1182/blood-2013-01-306647 (B1)